+

Diaceutics reviews the ongoing debate on diagnostics reform legislation

Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecular Diagnostics (May 2019). Citing the roots of this controversy, the authors cover the need for clinical laboratory standardization and harmonization as important keys to any regulatory reform. The article is entitled “Diagnostics Reform and Harmonization of Clinical Laboratory Testingand is available online here:    

https://www.sciencedirect.com/science/article/pii/S1525157818305919.  

 The article citation is: Schreier J, Feeney R, Keeling P. Journal of Molecular Diagnostics. 2019 May 8.   

The publication of this review article was also reported by CAP Today.

About Diaceutics
Diaceutics PLC is a leading diagnostic commercialization company for the global pharmaceutical industry. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.  www.diaceutics.com

Media Contact
Helen Morrogh
Tel: +353 1 215 7675
Email: helen@comit.ie
For more information, visit www.diaceutics.com or follow Diaceutics on Twitter, LinkedIn or Facebook

Latest Blogs

Latest Blogs